Other ongoing studies, such as NCT03125928 (phase IIA) and NRG-BR004 (phase III trial, randomized and double-blind), will evaluate the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in patients with locally advanced, unresectable, or metastatic HER2-positive breast cancer in the first-line setting. The gene discussed is ERBB2; the disease is breast cancer.